Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. (Nasdaq: MRTX), relating to its proposed sale to Bristol Myers Squibb. Under the terms of the agreement, MRTX shareholders will receive $58.00 and one CVR worth up to $12.00 in cash per share they own.